CJC-1295 and Ipamorelin are two different research peptides supplied together in one vial for laboratory use. Because a single vial holds two compounds, one purity figure cannot describe both of them. A useful certificate names which CJC-1295 variant is present, reports each component separately, and ties those results to the lot being shipped.
Cjc 1295 Ipamorelin Wholesale Coa Component Verification Cover
One number cannot describe two peptides
Start with the arithmetic, because it drives everything else.
The following is a hypothetical illustration. It is not a real certificate, not a real lot, and not any supplier's document. Picture a vial sold as a 10 mg blend of two peptides. A laboratory tests the contents and reports 99% purity. That figure says something narrower than it first appears. It says that 99% of what the instrument detected was peptide material rather than salts, solvents or synthesis byproducts.
It does not say the vial held the two peptides in the proportion you ordered. Both of the components in that vial are peptides. A vial weighted heavily toward one of them can still test at 99% purity, because the purity measurement is looking for contamination, not for balance. The number stays high while the composition drifts.
That gap is a structural property of any multi-component material. It is not an accusation against any supplier, and it does not disappear by choosing a better one. It only closes when the documentation reports each component on its own.
So the question for a wholesale buyer is not whether a purity figure looks good. The question is what the certificate has to say before that figure means anything at all.
What a purity percentage actually measures
Buyers tend to collapse several different things into the word purity. Pulling them apart is the fastest way to read a certificate properly.
Identity answers which molecule is present. Purity answers what proportion of the detected material was the intended peptide. Content answers how much peptide is actually in the vial by mass. Composition answers which components are present in a mixture. Ratio answers in what proportion they appear. Traceability answers whether the result belongs to the vial you will receive. Method answers how any of it was determined.
A single percentage speaks to one of those seven. Treating it as though it speaks to all of them is the most common reading error in peptide procurement.
Two practical consequences follow from that distinction. A purity figure carrying no lot number and no test date is not information you can act on, because nothing connects it to your material. And a high figure establishes nothing about sterility, endotoxin levels, water content or residual solvents, because the method was not looking for them. Absence of evidence on a certificate is not evidence of absence.
Our guide on how to read a certificate of analysis for peptides covers the general fundamentals. This article builds on them rather than repeating them.
The variant has to be named on the certificate, not just the label
Here is where blend documentation gets genuinely difficult, and where most buyers stop asking questions too early.
CJC-1295 is sold in two forms. One carries a modification that binds it to circulating albumin, and the other does not. These are different molecules with meaningfully different masses, and they are not interchangeable stock. A research program built around one of them is not served by the other.
The complication is that both forms circulate in public chemical listings under the same compound name. Search the registry layer and you will find entries labeled simply CJC-1295, with suppliers attaching different molecular formulas to overlapping identifiers. Some listings describe a structural modification without ever using the terms DAC or no-DAC. The identifiers do not reliably sort the two molecules apart.
We will not tell you which registry number belongs to which variant. The public sources conflict on that point. We could not resolve it against a primary record. That uncertainty is the finding, not a gap in the research. If the registry layer cannot settle variant identity, a buyer should never rely on it to do so.
Documentation is what settles the question instead. The certificate should name the variant explicitly. It should also support that name with a stated sequence and a measured mass for the lot in hand. Mass is the discriminating measurement here, because the two forms differ by a substantial margin.
The distinction in one line: a label naming a variant is a claim, and a certificate naming it with supporting data is a finding. Buyers pay for the second one and too often accept the first.
Worth knowing is that naming the variant is already standard practice elsewhere in this market. Browse retail listings for this compound pair and you will routinely see the no-DAC designation written into the product name. Asking a wholesale supplier to carry that same clarity onto the certificate is not an unusual demand.
The fields a blend certificate should carry
A certificate for a two-component vial needs to do more work than one for a single compound. These are the fields that make it useful.
| Field | What it establishes | What it leaves open |
|---|---|---|
| Lot number | Connects results to the material you receive | Nothing about quality by itself |
| Variant named | Which CJC-1295 form was tested | Whether the vial matches, absent supporting data |
| Per-component identity | That both peptides were found and confirmed | How much of each is present |
| Labeled against measured content | Whether the fill matches the declared mass | Component balance, unless reported separately |
| Test date | How current the result is | Whether later lots match |
| Method | How identity and purity were determined | Anything the method cannot detect |
| Testing party | Who performed the work | Independence, unless separately verifiable |
The labeled against measured line deserves particular attention, because it is the only field that checks the fill rather than the chemistry. Purity tells you about quality of material. A measured content figure tells you whether the vial holds what the label promises. Those are different failures, and a certificate reporting only the first leaves the second entirely unexamined.
Component reporting is the other field worth insisting on. Some certificates for blended material report one combined figure for the whole vial. Others report each peptide separately, with its own identity confirmation and its own result. Both formats exist in the market today for this exact compound pair. The second format answers a question the first cannot. A buyer who does not specify which one they need will sometimes receive the weaker version.
On ratio, be direct with your supplier. If the formulation ratio is not documented anywhere, you cannot confirm it, and you should not assume it from the product name. Ask whether the ratio is documented, and ask what the documentation shows. A supplier who can answer that question has thought about blend quality control. A supplier who deflects it to the quote stage has told you something too.
Eight questions to ask before you approve a blend supplier
Work through these questions during supplier evaluation. Each one includes what to request and what a good answer does not cover, because knowing the limits matters as much as getting the answer.
1. Can you provide a lot-specific certificate for the exact lot being quoted? Request the certificate carrying the lot number that will appear on the vials. A satisfactory answer connects documentation to material. It does not establish that the material is suitable, only that the paperwork refers to it. A generic example certificate answers a different question entirely, and should be treated as marketing rather than documentation.
2. Does the documentation analyze each component separately? Ask for per-component identity and purity results. A satisfactory answer tells you both peptides were found and measured individually. It does not tell you the proportion between them unless content figures are reported too. If only a combined figure exists, ask directly whether component-level testing is available.
3. Which laboratory performed the testing, and can the report be authenticated? Get the laboratory name, contact details and any report identifier. A satisfactory answer gives you a route to verify the document independently. It does not establish independence on its own. A supplier describing a laboratory as third-party is making a claim, not providing proof, and the same laboratories often serve multiple competing suppliers.
4. Which CJC-1295 variant is in this product, and what confirms it? Request the stated sequence and the measured mass. A satisfactory answer lets you check the variant against a reference. It does not help if the certificate names the variant without supporting data. Follow up by asking what the measured mass was, not merely which variant the label says.
5. What peptide content is declared per vial for each component, and how was it determined? Ask for both the declared figures and the method used. A satisfactory answer distinguishes nominal formulation from measured quantity. It does not confirm the ratio unless both components were measured. Watch for content and purity being quoted as though they were the same measurement.
6. What testing addresses contamination beyond purity? Find out which of endotoxin, residual solvents, heavy metals and water content were actually tested, and which were not. A satisfactory answer tells you the scope of what is known. It does not mean untested parameters are acceptable or unacceptable, only undocumented. Different research applications justify different panels, so the useful question is what applies to yours rather than demanding a universal list.
7. What research-use documentation accompanies the purchase? Request the actual attestation or agreement text. A satisfactory answer shows what responsibilities the arrangement places on you as the buyer. It does not establish that any particular transaction is lawful in your jurisdiction. An attestation is a term of sale, not a legal determination, and should never be read as one.
8. What are the confirmed purchasing terms for this product? Get the minimum order quantity, lead time, shipping origin and conditions, and replacement terms in writing. A satisfactory answer gives you terms you can plan against. It does not bind anything until it appears in a quote or agreement. Published policy and transaction-specific terms are different documents, and buyers are sometimes quoted against one while planning around the other.
Working through all eight does not guarantee product quality or regulatory compliance. No checklist of questions can do that. What it does is replace assumption with documentation, which is the only part of supplier evaluation a buyer actually controls.
Vetting the supplier organization is a separate job from reading product documentation. Our guide on how to verify a peptide supplier before ordering covers credential checks and red flags.
Stocking DAC or no-DAC comes down to what you can document
Research buyers stocking CJC-1295 face a variant decision before they face a format decision. This table frames it as a documentation problem, because that is how it actually presents.
| CJC-1295 with DAC | CJC-1295 without DAC | |
|---|---|---|
| Structural distinction | Carries a modification enabling binding to circulating albumin | Circulates as the unmodified peptide |
| What documentation must establish | Variant named, sequence stated, measured mass consistent with the modified form | Variant named, sequence stated, measured mass consistent with the unmodified form |
| What the name alone cannot establish | That the modification is present in the material supplied | That the modification is absent from the material supplied |
| What to ask before stocking | What measured mass was recorded, and against which reference | What measured mass was recorded, and against which reference |
| What remains unknown after reading the label | Everything above | Everything above |
Neither variant is superior to the other. A research requirement decides which one is appropriate. If your requirement does not specify, that is a question for your protocol rather than for your supplier. Where the requirement is unclear, the missing information is usually the intended duration of exposure in the experimental model, not anything a supplier can provide.
One consequence is easy to miss. A premixed blend makes the variant decision for you. Whoever formulated it chose, and your documentation either records that choice or it does not. If your program might need the other variant later, buying premixed locks in a decision you did not make.
Vial_kit_luxury
Buying the blend, the components separately, or one at a time
Format changes how much verification work an order creates. This matrix compares purchasing and documentation consequences only. It makes no claim about biological results, and the term stack here means a purchasing configuration, nothing about how material is used.
| Criterion | Premixed blend | Components bought separately | Single compound |
|---|---|---|---|
| Identities to verify | Two, in one vial | Two, in two vials | One |
| Per-component certificates | Only if the supplier reports that way | One per compound by default | One |
| Traceability | One lot covering both components | Separate lot per component | Single lot |
| Ratio documentation | Required, often absent | Not applicable, you control it | Not applicable |
| Flexibility if requirements change | Low, composition is fixed | High, components are independent | High |
| Documentation burden | Lowest paperwork, highest unknowns | More paperwork, fewer unknowns | Lowest overall |
The central trade-off runs opposite to intuition. A premixed vial looks simpler because it is one line on an order. It concentrates two identity questions, two content questions and one ratio question into a single certificate. Buying the components separately produces two certificates and removes the ratio question entirely, because you hold each compound independently.
That does not make premixed material a poor choice. It makes it a choice that carries a documentation requirement, and the requirement is that the certificate reports per component.
You can see the full range of available formats on our growth factor research catalog.
What the research actually shows and where it stops
Evidence for these compounds is frequently overstated in commercial material. Here is what the record supports, with the category of evidence named.
Human evidence for CJC-1295 with DAC. A randomized, placebo-controlled study appeared in the Journal of Clinical Endocrinology and Metabolism in 2006. It examined CJC-1295 with DAC in healthy subjects aged 21 to 61. Reported increases were 2 to 10 fold for growth hormone and 1.5 to 3 fold for IGF-I. This study examined the DAC-containing form alone. It was not a study of the blend, and it says nothing about the no-DAC variant.
Animal and in vitro evidence, Ipamorelin. A 1998 paper in the European Journal of Endocrinology characterized Ipamorelin as a selective growth hormone secretagogue. The work used rat pituitary cells, anesthetized rats and conscious swine. All of that work is preclinical rather than clinical. It is not human evidence, and findings in these models do not transfer to human outcomes.
Evidence for the two compounds combined. We identified no published human trial of the CJC-1295 and Ipamorelin combination. A mechanistic rationale for combining them exists, and a rationale is not a result. Any claim that the blend produces a particular outcome in humans is unsupported by the published record.
Why this matters for procurement teams. A 2026 narrative review in Sexual Medicine Reviews looked at this compound class. It noted that secretagogues reliably raise growth hormone and IGF-1 concentrations. Evidence for functional benefit remains limited. The same review observed that CJC-1295 and related compounds remain accessible through unregulated markets, raising concerns about product quality and variability. That is a peer-reviewed source identifying material quality as a live problem in this compound class. Component-level documentation is worth the effort for exactly that reason.
Sources are listed at the end of this article.
For the current regulatory picture around research-use sourcing, see our guide on peptide sourcing in 2026.
The purchasing details to confirm before an order
A few terms are published and a few are not. Knowing which is which saves a round of emails.
Our published minimum is 10 units, which is one kit, per product specification. Volume bands are structured by monthly kit volume, with thresholds at 1 to 9, 10 to 19, 20 to 39, and 40 or more kits. Domestic orders typically ship within 1 to 2 business days after payment confirmation, with transit to most US states running 2 to 4 business days.
Prices are not published on this site. Wholesale rates are quoted per account, because they move with volume, compound and current supply conditions. Request current rates through the quote route rather than working from any figure you find online. How volume thresholds work in practice is covered in our breakdown of wholesale peptide pricing tiers.
Batch documentation for a specific product is available on request before you commit to an order. You can start that request through our certificates of analysis page.
Before you place the order
Work the sequence in the order below. Confirm which variant the product contains and what data supports it. Check that the certificate is lot-specific and current. Confirm that each component was analyzed separately, and that declared content is stated per component. Ask what contamination testing was performed and what was not. Then confirm your purchasing terms in writing.
None of that is an exotic request. It is the documentation a two-component research material should already carry, and asking for it costs a single email.
To request current batch documentation and wholesale terms for any compound in our catalog, contact our B2B team directly.
Chromatography_lab
References
- Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID 16352683. DOI 10.1210/jc.2005-1536
- Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552-561. PMID 9849822. DOI 10.1530/eje.0.1390552
- Vasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sex Med Rev. 2026;14(4). PMID 42862021. DOI 10.1093/sxmrev/qeag078
All compounds referenced are supplied for research use only. They are not FDA approved and are not intended for human or veterinary consumption, clinical diagnostics, or therapeutic use. This article does not provide dosing, administration, or handling instructions for human use.
